Background: TGF-b1 controls many pathophysiological processes including tissue homeostasis, fibrosis, and cancer progression. Together with its latency-associated peptide (LAP), TGF-b1 binds to the latent TGF-b1-binding protein-1 (LTBP-1), which is part of the extracellular matrix (ECM). Transmission of cell force via integrins is one major mechanism to activate latent TGF-b1 from ECM stores. Latent TGF-b1 mechanical activation is more efficient with higher cell forces and ECM stiffening. However, little is known about the molecular events involved in this mechanical activation mechanism. Results: By using single-molecule force spectroscopy and magnetic microbeads, we analyzed how forces exerted on the LAP lead to conformational changes in the latent complex that can ultimately result in TGF-b1 release. We demonstrate the unfolding of two LAP key domains for mechanical TGF-b1 activation: the a1 helix and the latency lasso, which together have been referred to as the ''straitjacket'' that keeps TGF-b1 associated with LAP. The simultaneous unfolding of both domains, leading to full opening of the straitjacket at a force of w40 pN, was achieved only when TGF-b1 was bound to the LTBP-1 in the ECM. Conclusions: Our results directly demonstrate opening of the TGF-b1 straitjacket by application of mechanical force in the order of magnitude of what can be transmitted by single integrins. For this mechanism to be in place, binding of latent TGF-b1 to LTBP-1 is mandatory. Interfering with mechanical activation of latent TGF-b1 by reducing integrin affinity, cell contractility, and binding of latent TGF-b1 to the ECM provides new possibilities to therapeutically modulate TGF-b1 actions.
Introduction
TGF-b1 is a pleiotropic cytokine that controls cell growth, inflammation, tissue homeostasis, and immune suppression in a variety of normal and pathologic adult tissues [1] [2] [3] [4] . TGF-b1 is also an important therapeutic target because of its involvement in the pathogenesis of many disorders, including organ fibrosis and tumorigenesis. The unsuccessful outcomes of blocking the already active TGF-b1 in animal experiments and clinical tests in combination with the risk of uncontrollable side effects has shifted research toward preventing latent TGF-b1 activation in a cell type-and activation mechanismspecific manner [5] [6] [7] [8] [9] [10] [11] . TGF-b1 is synthesized as part of a proprotein that is intracellularly cleaved to produce the small latent complex (SLC) ( Figure 1A ). Mature SLC consists of the TGF-b1 dimer, noncovalently linked to the dimeric latencyassociated peptide (LAP). Most cell types secrete SLC together with latent TGF-b-binding protein-1 (LTBP-1), constituting the large latent complex (LLC) [12, 13] . LTBP-1 targets latent TGF-b1 to the extracellular matrix (ECM) by interacting with different proteins including fibronectin and fibrillin [14, 15] , generating deposits of latent TGF-b1 accessible for cell-mediated activation [16] [17] [18] (Figure 1A ).
Integrins have emerged as central players in TGF-b1 activation [10, 18, 19] . The expression of cell type-characteristic integrin sets provides means to interfere with TGF-b1 activation in a tissue-or cell-specific manner [10, [20] [21] [22] [23] . Epithelial cells activate latent TGF-b1 via integrin avb6 [16, 24] , whereas fibroblasts, devoid of avb6 integrin, appear to promote latent TGF-b1 activation through integrins avb3, avb8, and avb5 [10, [20] [21] [22] [23] . Integrins activate latent TGF-b1 by at least two different mechanisms [18, 19] . One depends on proteases, which seem to be guided to the LLC by associating with integrins [10, 17] . The other is independent of proteolysis and involves transmission of cell traction forces to the LAP moiety of LLC [17] [18] [19] . We and others have proposed that ECM-bound LTBP-1 provides mechanical resistance against cell-mediated contraction to induce a conformational change in LAP that leads to liberation of active TGF-b1 [16, 21, 25] . This mechanical mode of action seems to play a major role in stiff fibrotic scars [18, 21, 26] .
To specifically interfere with mechanical TGF-b1 activation, it is essential to characterize the molecular events involved in this process. The recently resolved crystal structure of the SLC has revealed a particular conformation. Whereas the overall LAP structure is predicted to be mechanically stable, two stretches in the molecule are prone to unfolding: the a1 helix and the latency lasso loop [25] . Together both domains form a configuration that traps TGF-b1 in the SLC like a ''straitjacket'' [25] . The structure data predict that complete opening of the straitjacket leads to release of the active TGF-b1 from LAP [25] . To this end, opening of the straitjacket by mechanical force has not been experimentally proven.
To provide experimental evidence for a force-induced conformational change, we performed force spectroscopy with the atomic force microscope (AFM), and we made three fundamental discoveries. (1) Mechanical force applied to LAP can unfold the a1 helix and the latency lasso in the straitjacket. (2) Simultaneous unfolding of both domains and full opening of the straitjacket is possible only when LAP is bound to LTBP-1. (3) In the context of the LLC, fully unraveling the straitjacket requires lower forces (w40 pN) than does unfolding of its individual stretches (w50 pN). Together our data favor an all-or-nothing snap mechanism of full TGF-b1 release by mechanical force.
Results

Unfolding of Recombinant SLC and LAP
We first compared the unfolding profiles of recombinant SLC (TGF-b1-loaded) and LAP (empty) adsorbed onto mica substrates in the absence of LTBP-1 ( Figure 1 ). TGF-b1-loading of protein layers was tested by incubating transformed mink lung epithelial (tMLEC) reporter cells with the liquid phase from untreated (active TGF-b1) and heat-activated (total TGF-b1) SLC/LAP-coated samples. Only 15% of the SLC spontaneously released TGF-b1; no TGF-b1 activity was measured from LAP-coated mica ( Figure 1B ). SLC and LAP were then pulled with AFM probes covalently coated with anti-LAP monoclonal antibodies. Because forces measured in AFM depend on the linker flexibility and rate of stressing [27] , we used a loading rate of w10,000 pN/s, comparable with integrin-ligand interaction studies [28] [29] [30] [31] . To determine the increase in protein contour length (DLc), i.e., the pulling distance to unfold a protein domain, and to extract unfolding forces, the worm-like chain model [32] was fitted to individual unfolding events ( Figure 1C ). DLc and unfolding forces for all of (C) Force-extension traces were obtained after stretching single LAP or SLC molecules with an AFM tip covalently coated with LAP antibodies. A low pulling speed of 200 nm/s was selected to prevent unfolding of the antibodies that deform only at higher pulling rates [50] . Worm-like chain fitting (black lines) was applied to extract DLc and unfolding forces. (D and F) DLc values were summarized in frequency histograms for SLC (D) and LAP (F) and event populations (red dashed lines) were detected; arrowheads indicate population maxima. (E and G) DLc-force pairs for every individual unfolding event were plotted in bivariate color-coded contour plots for SLC (E) and LAP (G). Blue represents low and red high frequency of events.
the events were summarized in histograms (Figures 1D and 1F ; Figure S1 available online); to discriminate event populations, Gaussian mixture models were fitted to the data.
Fitting the DLc distributions of SLC revealed three populations centered at 7.1 6 1.6 nm, 11.1 6 2.8 nm, and 17.5 6 7.9 nm ( Figure 1D ). Three DLc populations were also determined for LAP, with maxima at 12.0 6 2.6 nm, 19.0 6 4.5 nm, and 26.9 6 9.5 nm ( Figure 1F ). DLc and force cannot be directly correlated based on the peak order of the histograms. To retain the information of which force corresponds to each DLc peak, both parameters of every unfolding event were plotted in bivariate diagrams; maxima in the frequency of occurrence of DLc/force pairs appear in red/yellow ( Figures 1E and 1G ). Bivariate plots revealed clear differences between SLC and LAP unfolding characteristics ( Figures 1E  and 1G ). SLC unfolding presents one main event population at 8.1 nm/44.9 pN, whereas LAP unfolding shows three populations at 11.0 nm/46.5 pN, 13.6 nm/74.1 pN, and 12.1 nm/115.5 pN.
Analysis of LAP Structural Domains
These different unfolding characteristics suggest that LAP attains a stable new conformation after TGF-b1 release. We subsequently analyzed whether the DLcs measured in recombinant LAP and SLC corresponded to the lengths of important structural domains of the LAP moiety. Recently published 3D structure data indicate that the LAP moiety is folded in two principal regions, the straitjacket (Leu30-Pro74) and the arm (Glu75-Arg278) [25] . Of those, only the a1 helix (Leu30-Arg58) and the latency lasso (Leu59-Pro74) domains on the straitjacket are expected to unfold under stretch (Figure 2A ) [25] . Based on these premises, we analyzed whether the DLcs experimentally measured in recombinant LAP and SLC corresponded to the lengths of any of these structural domains. Expected domain lengths were calculated by multiplying the number of residues by 0.4 nm, the average length of one amino acid (aa) [33] ; we allowed a DLc variance of 610%. To filter for the a1 helix, we scanned for DLc of 11.2 6 1.2 nm (28 6 3 aa); DLc intervals of 6.8 6 0.8 nm (17 6 2 aa) were defined for the latency lasso. Additionally, we filtered for DLc of 18.0 6 1.6 nm (45 6 4 aa), corresponding to the whole straitjacket (a1 helix and latency lasso). These DLc values were also predominant in the SLC and LAP histograms ( Figures 1D and 1F ). Bivariate plots of DLc-force pairs were then generated, containing only events with DLc attributed to these defined domains ( Figures 2B and 2C ). Unfolding events with DLc corresponding to the 17 aa latency lasso were frequent in TGF-b1-loaded SLC ( Figure 2B ) but virtually absent in empty LAP ( Figure 2C ). A pulling force of 47.8 pN was required to unfold the 6.8 nm latency lasso domain and a force of 80.8 pN to unfold the 11.2 nm a1 helix domain of SLC (Table S1 ). For the few unfolding events identified in SLC and LAP with DLc matching the 18.0 nm-long entire straitjacket, forces were lower (w35 pN) than for the individual domains. Controls performed with bare mica did not produce any of these events ( Figure S3 ). Pulling with the same antibody gave different profiles for LAP and SLC; hence, unfolding of the probing antibody did not contribute to the data. Probing recombinant LAP and SLC with nonspecific antibodies did not deliver any unfolding events (unpublished data).
Mechanical Activation of TGF-b1 from the ECM Cell-mediated mechanical activation of latent TGF-b1 was shown to require immobilization of the SLC in the ECM via covalent binding to LTBP-1 [16, 21] , which potentially alters the force needed to unfold SLC. We first established the profile of force-induced unfolding of LTBP-1 alone to later discriminate unfolding events in the SLC/LAP moiety of the LLC from LTBP-1 unfolding events ( Figure 3 ). To specifically target the AFM probe to LTBP-1 in the ECM, we produced red fluorescent LTBP-1 with LTBP-1-mRFP-transfected CHO cells. Wild-type CHO cells did not express LTBP-1 or LAP-TGF-b1 ( Figure 3A ). Similar to transfected nontagged LTBP-1, LTBP-1-mRFP in the ECM was organized in patches and fibrils after 5-7 days of culture ( Figure 3A ). Whereas LTBP-1 patches were deposited onto the substrate, fibrils were organized between cells ( Figures 3A and 3C ). Fibrils but not patches partially colocalized with other ECM proteins including fibronectin (Figure S4 , Movie S1), fibrillin-1, and fibrillin-2 (unpublished data). We removed cells and fibrils with desoxycholate (DOC) (Figure 3B ) before patches of red fluorescent LTBP-1 were targeted with the LTBP-1 antibody-coated AFM probe.
Force-distance profiles were generated for LTBP-1-mRFP, analyzed, and summarized in histograms as described for LAP and SLC ( Figures 3D, 3E , S1). Four DLc event populations at 14.8 6 5.0 nm, 26.8 6 8.6 nm, 47.0 6 12.2 nm, and 78.7 6 9.7 nm were identified ( Figure 3E ). Unfolding forces for LTBP-1 are summarized in Figure S1 . Bivariate plots of DLcunfolding force pairs per every single event displayed three distinct peaks at 16.7 nm/179.4 pN, 22.6 nm/68.2 pN, and 34.5 nm/39.8 pN ( Figure 3F ). Thus, unfolding of the LTBP-1 resulted in a combination of short stretch-resistant domains and long flexible domains. Importantly, all these unfolding events were distinct from those observed in the recombinant SLC/LAP proteins.
To pull the SLC as an integral part of the LLC, we next coexpressed LTBP-1 and LAP-TGF-b1 constructs in CHO cells. Confocal microscopy of immunostained ECM before ( Figure 4A ) and after ( Figures 4B and 4C ) DOC extraction demonstrated that transfected LAP, TGF-b1, and LTBP-1 all colocalized. In DOC-extracted ECM, LLC appears as a layer of w1 mm-thick patches with LAP and TGF-b1 on top of LTBP-1, colocalizing in the upper part of confocal z-sections ( Figure 4D ). Because a substantial fraction of LTBP-1 did not contain SLC ( Figures 4B and 4C, blue) , detection of LTBP-1-mRFP alone was not suitable to guide the AFM probe to the LLC; therefore, we also provided the SLC with a fluorescent tag. We ultimately selected a construct with EYFP located N-terminally to the signal peptide of the LAP-TGF-b1 prepro-protein (EYFP-LAP). Cells transfected with this construct retained cytoplasmic EYFP but secreted LAP without the EYFP, hence without sterical alterations ( Figure 5A ). Only EYFP-positive CHO-LTBP-1 cells accumulated extracellular LAP ( Figure 5A ). Western blotting confirmed the presence of EYFP in extracts from EYFP-LAP-transfected CHO-LTBP-1 cells and its absence from conditioned medium ( Figure 5B ). Importantly, tMLEC cells reported high levels of TGF-b1 in heat-activated conditioned medium ( Figure 5C ). Hence, LAP-TGF-b1 was deposited as LLC onto the substrate after intracellular cleavage of EYFP and TGF-b1 could be activated. We also attempted to add EGFP to the TGF-b1 moiety (TGF-b1-EGFP) ( Figure 5 ). Although several tests suggested that TGF-b1-EGFP SLC was produced and secreted together with LTBP-1, the EGFP-tagged TGF-b1 was not adequately matured and was not released from the LLC (Figures 5 and  S5 ). These constructs were not pursued.
For AFM stretching experiments, the position of EYFP-LAPpositive cells with abundant LTBP-1-mRFP ( Figure 6A ) was recorded using coverslips with grids. Cells and fibrils were then DOC extracted and LTBP-1-mRFP was relocalized. Pulling on the LTBP-1-mRFP-LAP complex with a LAP antibody-coated AFM probe produced multiple unfolding events ( Figure 6B ). In DLc histograms, we identified four populations at 10.8 6 2.4 nm, 17.2 6 4.2 nm, 27.8 6 7.5 nm, and 46.9 6 20.0 nm ( Figure 6C ). In unfolding forces histograms, we detected four populations at 32.6 6 12.9 pN, 68.7 6 23.7 pN, 141.1 6 45.4 pN, and 268.2 6 40.4 pN ( Figure S1 ). Comparison of distributions of LLC with individual LLC components is provided in Figure S2 .
Summarizing data in DLc-force pair plots revealed two dominant populations at 14.8 nm/61.2 pN and 18.8 nm/43.7 pN ( Figure 6D ). Filtering for LAP/SLC domain unfolding events ( Figure 6E ) delivered two event populations corresponding to the a1 helix domain (11.4 nm/51.2 pN) and to the whole straitjacket (18.3 nm/38.6 pN) (Figure 2A ; Table S1 ). Control experiments with LAP antibody-( Figure 6F ) or nonspecific antibody (unpublished data) -coated AFM probes did not reveal any of these populations in LTBP-1 ECM.
It has been predicted from the SLC crystal structure that straitjacket opening will necessarily lead to TGF-b1 release [25] . If this were true, TGF-b1 should be released into the medium upon force application to single LLC complexes through the LAP moiety. Because TGF-b1 could not be activated from SLC formed with fluorescently tagged TGF-b1 ( Figures 5 and S5 ) and because one single TGF-b1 molecule is below the detection sensitivity of tMLEC reporter cells, we employed a different pulling assay. Ferromagnetic beads were coated with LAP antibody or with recombinant integrin avb6, the most potent LAP-binding and TGF-b1-activating integrin [16, 34] . Bovine serum albumin (BSA)-coated microbeads were used as controls. Microbeads were adsorbed onto DOC-extracted LLC-rich ECM. All controls with no force application exhibited low levels of active TGF-b1 in the medium, reaching 15%-20% of total TGF-b1 available in the ECM (Figure 7A) . Applying magnetic force to BSAcoated beads led to the release of active TGF-b1 of w25% of total TGF-b1 ( Figure 7A ), probably because of nonspecific shear forces that are able to activate TGF-b1 [35] . In contrast, pulling anti-LAP-and avb6 integrin-coated beads released 1.7-to 2.2-fold higher quantities of active TGF-b1 (w40% and 50% of total TGF-b1, respectively) compared with BSA-coated magnet-pulled beads ( Figure 7A ).
Discussion
We have recently established that transmission of cell contractile forces to LAP via integrins activates latent TGF-b1 reservoirs from noncompliant ECM [21] . We here demonstrated at the single-molecule level that pulling on LAP will induce conformational changes, attributed to TGF-b1 activation. Our findings are consistent with previous studies suggesting that TGF-b1 activation involves conformational changes in the N-terminal portion of LAP, which confers latency by binding to TGF-b1 [25, [36] [37] [38] [39] [40] . The recently published 3D structure of the SLC revealed two structures that interact with TGF-b1 in this LAP region: the a1 helix and the latency lasso, together forming a straitjacket that traps TGF-b1 [25] (Figure 2A) . In contrast to the remaining LAP molecule, which is packed in a force-resistant structure, the a1 helix and the latency lasso are ill-suited to withstand force and would be most susceptible to be unfold upon mechanical stretch [25] .
Our pulling experiments with recombinant proteins demonstrate that both the a1 helix and latency lasso are central in mechanical activation of latent TGF-b1. First, a domain length corresponding to the 17 aa latency lasso is detected only when TGF-b1 associates with LAP, suggesting that TGF-b1 stabilizes the conformation of this domain in the SLC. Second, unfolding of the 28 aa a1 helix domain in SLC requires forces w2-fold higher than in the empty LAP (Table S1 ). Both findings are consistent with the concept that interactions linking structural motifs in strategic positions generally alter protein unraveling characteristics [41] . TGF-b1 seems to stabilize the SLC by reinforcing the a1 helix, which holds TGF-b1 in the LAP. Their different susceptibility to mechanical stretch indicates the potential of the a1 helix and latency lasso as force sensors.
In vivo, SLC binding to LTBP-1 in the ECM establishes mechanical resistance to integrin-mediated cell pulling [16, 21] . By coexpressing the LLC components via mammalian cells, we provided a simplified yet physiologically relevant ECM model for AFM experiments. Most remarkably, events corresponding to unfolding of the entire straitjacket were predominant in the LLC but occurred with low frequency in the SLC. This lever effect of LTBP-1 can be explained by the overlap of the TGF-b1 and LTBP-1 binding epitopes close to the N terminus of LAP (Arg45-Leu59) in the a1 helix region [40] . This leverage anchoring point on the LTBP-1 has important implications for the force needed to activate TGF-b1 from ECM-bound LLC. The presence of the LTBP-1 lever increases the probability of unfolding the entire straitjacket, by lowering full straitjacket unfolding forces (w40 pN) below the forces needed for unfolding its latency lasso (w50 pN) and a1 helix subdomains (w80 pN) (Table S1 ). Our results further indicate that adsorption of SLC to ECM components other than LTBP-1 [18] does not lower the full straitjacket unfolding force and thus will not have the same leverage effect. Our data together with the crystal structure of SLC indicate full opening of the LAP straitjacket upon LLC pulling, supporting an ''all-or-nothing'' model of TGF-b1 release upon activation ( Figure 7B ). The question remains how mechanical TGF-b1 activation can be regulated in such a model. Because straitjacket opening and TGF-b1 release from the LLC need to overcome a pulling force threshold, regulation probably occurs at the level of force build-up. This control can imply modulation of (1) intracellular force development by actin/ myosin interaction, (2) integrin binding affinity and strength by feedback force or chemical signals, and (3) ECM stiffness and resistance to integrin pulling. All these premises are in agreement with our previous observation that TGF-b1 activation is modulated by the level of cell-generated tension and that ECM stiffness has to exceed a threshold to result in mechanical TGF-b1 activation [21] . A compliant ECM does not oppose cell-derived contractile forces and LAP unfolding will be impaired, regardless of the cell contraction strength ( Figure 7B) . A stiff ECM, however, provides the necessary resistance to promote a full conformational change of the LAP and TGF-b1 release by cell contraction ( Figure 7B ).
Unfolding the TGF-b1 straitjacket in the LLC was achieved with pulling forces of w40 pN, which is in the range of forces transmitted by single integrins (tens of pN up to 165 pN) [28] [29] [30] [31] 42] . Hence, one integrin would be sufficient to transmit the force required to unfold the latent TGF-b1 structure. These force values, obtained with single-molecule AFM, are different from values obtained from microbead pulling experiments, which typically deliver at least 10-to 100-fold lower integrin forces [43, 44] . This discrepancy partly originates from the fact that microbead experiments average force values over the number of possible integrin-ligand interactions on the bead surface. However, not all integrins on the bead surface will be bound, leading to a systematic underestimation of single integrin force. Importantly, magnetic microbeads can exert the forces that are needed to directly activate and release TGF-b1 from a LLC ECM in our experiments, demonstrating for the first time mechanical TGF-b1 activation in a cell-free system.
Another important finding of our study is that pulling on the SLC portion of the LLC can lead to unfolding events in the LTBP-1, as seen from comparison with profiles obtained from pulling LTBP-1 in the absence of SLC. The LTBP-1 backbone comprises repeats of epidermal growth factor (EGF)-like domains interspersed with 8-Cys repeats, of which the third 8-Cys repeat binds LAP via disulfide bonds ( Figure 1A ) [45] . The average length of one completely unfolded EGF-like repeat is 15.2-16.0 nm (38-40 aa) and the average length of one 8-Cys domain is 21.6 nm (54 aa) [46] . Thus, pulling on SLC in LLC appears to unfold EGF-like domains in the LTBP-1 (e.g., at 14.8 nm/61.2 pN). Although we did measure frequent unfolding events in LTBP-1 that could correspond to 8-Cys domains (e.g., at 22.6 nm/68 pN), we did not observe such events when probing the LLC. Unfolding of 8-Cys domains is unlikely, possibly because of internal domain disulfide bonds that are difficult to unfold [33] , acting as a mechanical barrier to prevent the disassembly of the TGF-b1-binding domain upon integrin pulling. Finally, the two maxima with longer DLc observed in both LTBP-1 and LLC (27.8 6 7.5 nm and 46.9 6 20.0 nm) may correspond to partially unfolded LTBP-1 domains, because they exhibit lower resistance to stretch and their length consists of a multiple of the EGF-like domain length.
In summary, we have characterized the mechanical stress involved in TGF-b1 activation from SLC and LLC at the molecular level and demonstrated TGF-b1 release upon force transmission to LAP. A force of >40 pN is required to unfold LAP domains critical for providing TGF-b1 latency in the LLC. It is thus conceivable that mechanical activation of latent TGF-b1 is restricted to integrins with high binding affinity to LAP, to cells that can transmit considerable force to the LAP, and to a sufficiently rigid ECM. Hence, pharmacological interference with either factor will affect TGF-b1 activation. Importantly, therapeutic strategies to block harmful TGF-b1 activity in fibrosis or cancer progression could already be effective when integrin binding and cell contraction are decreased below the TGF-b1 activation threshold without completely blocking either process.
Experimental Procedures
Plasmid Constructs, Cell Culture, and Transfection To allow live detection, we produced fluorescent fusion proteins of all human LLC components (see Supplemental Information); EYFP-LAP-b1 (EYFP-LAP) was commercially obtained (IOH4479-pdEYFP-C1amp, imaGenes GmbH, Germany). Recombinant proteins were expressed in Chinese hamster ovary (CHO K1) cells after transient transfection via JetPei (PolyPlus-transfection SA, France) according to manufacturer's instructions. CHO cells, stably transfected with LTBP-1S (CHO-LTBP-1), were a kind gift from D. Rifkin [16] . We used 10 mg/ml recombinant SLC/LAP to coat mica surfaces (R&D Systems, MN). Lab reagents were obtained from Sigma (Switzerland).
ECM Preparation, Immunofluorescence Staining, and Light Microscopy ECM containing different LLC components was produced by plating transfected CHO cells for 7 days on glass coverslips or on 35 mm ''m-dishes'' with grid (IBIDI GmbH, Germany) in serum-free conditions. Pure ECM was obtained by removing cells with ice-cold desoxycholate (DOC) buffer (0.5% DOC, 1% NP-40, 150 mM NaCl in 10 mM Tris-HCl [pH 8.0]) for 10 min, followed by washing with PBS. Only protein layers intimate to the culture surface were preserved after DOC extraction of CHO cells. We have preferred this approach over using purified LTBP-1 and LLC to preserve proper folding and conformation of protein complexes and to avoid loss of TGF-b1 from the LLC during purification. Extracellular LLC components on whole-cell preparations were immunostained by incubating living cells with the corresponding primary antibodies (2 hr, 37 C), followed by fixation and incubation with secondary antibodies omitting permeabilization. LLC components from fresh DOC-extracted samples were stained similarly. Fluorescence imaging was performed with a SP2 Leica AOBS inverted confocal microscope (Leica Microsystems GmbH, Germany) and deconvoluted with HuygensPro (SVI, The Netherlands).
TGF-b1 Activity Measurements
To measure active TGF-b1, tMLEC reporter cells [47] were incubated with TGF-b1-containing solutions for 18 hr. To measure total TGF-b1, samples were heat treated 10 min at 80 C [21] . tMLEC were then lysed and luciferase activity was quantified with a luciferin substrate (Promega, WI) in a Centro LB Luminometer (Berthold Technologies, Germany). TGF-b1 levels are expressed as mean 6 SD of at least three independent experiments performed in duplicate.
AFM-Force Spectroscopy and Statistical Analysis
Gold-coated Si 3 N 4 cantilevers (Microlevers, Veeco, CA) with an average measured spring constant of 0.045 6 0.014 N/m were coated with 20 mg/ml of monoclonal LAP or LTBP-1 antibody (for details see Supplemental Information). AFM measurements were performed with the Nanowizard II (JPK Instruments, Germany) mounted onto the stage of a Zeiss 200M inverted epifluorescence microscope (Carl Zeiss, Germany). We set the pulling speed at 200 nm/s, corresponding to a loading rate of w10,000 pN/s, comparable with similar studies [28] [29] [30] [31] . All force-extension curves showing (E) All force-extension curves from LLC were analyzed for DLcs that would correspond to the length of domains predicted to be critical for TGF-b1 storage in LAP (see Figure 2 ). All LLC unfolding events falling in either of the search windows defined by the domain theoretical DLc (dashed lines) 6 10% (dotted lines) were plotted in a bivariate DLc-force contour map. (F) No LAP domains were detected in LTBP-1 when pulled with LAP antibodies (control), demonstrating the specificity of LLC measurements.
protein unfolding events upon pulling were analyzed. The contour length (Lc) for each unfolding event in the force-extension AFM curves was obtained via a wormlike chain model [32] :
where kB is Boltzmann's constant, T is temperature, p is persistence length (fixed at 0.4 nm), and x is extension. Curves were fitted with the JPK Imaging Processing software (JPK Instruments). All data points for DLc and unfolding forces were summarized in frequency histograms (percent of all events) and provided with Gaussian fits (Supplemental Information) [48] . In text, maxima of the Gaussian fittings are expressed 6 SD. To directly relate force and DLc for every unfolding event, pairs of DLc and force were plotted on three-dimensional color-coded maps (Supplemental Information) [49] . To better determine the force necessary to unfold SLC/LAP key domains, we filtered the curves that presented events compatible with the lengths of these protein domains (Supplemental Information). Filtered data were displayed in bivariate color-coded plots of DLc over force. All data analysis was performed with MatLab v 7.9 (The MathWorks, MA).
Force Application via Ferromagnetic Microbeads
To directly demonstrate force-mediated release of active TGF-b1 from LLC ECM, we used ferric oxide microparticles (Sigma) and a permanent ceramic magnet. Beads were coated with 10 mg of LAP antibodies (R&D Systems), recombinant human integrin avb6 (R&D Systems), or BSA (BioShop Canada Inc., ON). Beads were then washed in PBS and resuspended in fresh serumfree tMLEC medium. DOC-extracted ECM of LLC-expressing cells was incubated with coated beads (30 min) before multidirectional force was applied with the magnet. TGF-b1 released from LLC was measured with tMLEC reporter cells.
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures, five figures, one table, and one movie and can be found with this article online at doi:10.1016/j.cub.2011.11.037.
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